1. Home
  2. STTK vs SMID Comparison

STTK vs SMID Comparison

Compare STTK & SMID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • SMID
  • Stock Information
  • Founded
  • STTK 2016
  • SMID 1960
  • Country
  • STTK United States
  • SMID United States
  • Employees
  • STTK N/A
  • SMID N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • SMID Building Materials
  • Sector
  • STTK Health Care
  • SMID Industrials
  • Exchange
  • STTK Nasdaq
  • SMID Nasdaq
  • Market Cap
  • STTK 37.6M
  • SMID 157.4M
  • IPO Year
  • STTK 2020
  • SMID 1995
  • Fundamental
  • Price
  • STTK $0.79
  • SMID $35.88
  • Analyst Decision
  • STTK Hold
  • SMID
  • Analyst Count
  • STTK 4
  • SMID 0
  • Target Price
  • STTK $3.00
  • SMID N/A
  • AVG Volume (30 Days)
  • STTK 470.6K
  • SMID 20.7K
  • Earning Date
  • STTK 07-31-2025
  • SMID 07-10-2025
  • Dividend Yield
  • STTK N/A
  • SMID N/A
  • EPS Growth
  • STTK N/A
  • SMID 444.88
  • EPS
  • STTK N/A
  • SMID 1.86
  • Revenue
  • STTK $4,606,000.00
  • SMID $84,450,000.00
  • Revenue This Year
  • STTK N/A
  • SMID N/A
  • Revenue Next Year
  • STTK N/A
  • SMID N/A
  • P/E Ratio
  • STTK N/A
  • SMID $20.43
  • Revenue Growth
  • STTK 69.65
  • SMID 33.01
  • 52 Week Low
  • STTK $0.69
  • SMID $25.13
  • 52 Week High
  • STTK $4.99
  • SMID $51.96
  • Technical
  • Relative Strength Index (RSI)
  • STTK 39.92
  • SMID 64.79
  • Support Level
  • STTK $0.75
  • SMID $32.85
  • Resistance Level
  • STTK $0.85
  • SMID $39.93
  • Average True Range (ATR)
  • STTK 0.08
  • SMID 1.48
  • MACD
  • STTK -0.01
  • SMID 0.50
  • Stochastic Oscillator
  • STTK 10.56
  • SMID 69.46

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

Share on Social Networks: